Emerging therapeutics targeting mRNA translation

Cold Spring Harbor Perspectives in Biology

Volumn 4, Issue 4, 2012, Pages

  Malina, Abba ^a   Mills, John R ^a   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EUKARYOTA;

INITIATION FACTOR 4F; MESSENGER RNA;

ARTICLE; GENETICS; HUMAN; METABOLISM; NEOPLASM; PROTEIN SYNTHESIS;

EUKARYOTIC INITIATION FACTOR-4F; HUMANS; NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER;

EID: 84875147737     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a012377     Document Type: Article

References (142)

1. Adams BL, Morgan M, Muthukrishnan S, Hecht SM, Shatkin AJ. 1978. The effect of "cap" analogs on reovirus mRNA binding to wheat germ ribosomes. Evidence for enhancement of ribosomal binding via a preferred cap conformation. J Biol Chem 253: 2589-2595.
2. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, et al. 2010. Pathway-based identification of biomarkers for targeted therapeutics: Personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2: 43ra55.
3. Babendure JR, Babendure JL, Ding JH, Tsien RY. 2006. Control of mammalian translation by mRNA structure near caps. RNA 12: 851-861.
4. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. 1996. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 15: 658-664.
5. Bordeleau ME, Matthews J, Wojnar JM, Lindqvist L, Novac O, Jankowsky E, Sonenberg N, Northcote P, Teesdale-Spittle P, Pelletier J. 2005. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci 102: 10460-10465.
6. Bordeleau ME, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, Belsham GJ, Wagner G, Tanaka J, Pelletier J. 2006a. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol 2: 213-220.
7. Bordeleau ME, Cencic R, Lindqvist L, Oberer M, Northcote P, Wagner G, Pelletier J. 2006b. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem Biol 13: 1287-1295.
8. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco JA Jr, et al. 2008. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 118: 2651-2660.
9. Brown CJ, Lim JJ, Leonard T, Lim HC, Chia CS, Verma CS, Lane DP. 2011. Stabilizing the eIF4G1 a-helix increases its binding affinity with eIF4E: Implications for peptidomimetic design strategies. J Mol Biol 405: 736-753.
10. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. 1998. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci 95: 1432-1437.
11. Buxade M, Parra-Palau JL, Proud CG. 2008. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci 13: 5359-5373.
12. Cai A, Jankowska-Anyszka M, Centers A, Chlebicka L, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoads RE. 1999. Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation. Biochemistry 38: 8538-8547.
13. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, et al. 2008. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
14. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, et al. 2009a. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE 4: e5223.
15. Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J. 2009b. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acutemyelogenous leukemia cells. Leuk Res 34: 535-541.
16. Cencic R, Desforges M, Hall DR, Kozakov D, Du Y, Min J, Dingledine R, Fu H, Vajda S, Talbot PJ, et al. 2011a. Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol 85: 6381-6389.
17. Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, Qui M, Lewis I, Kurtkaya S, Dingledine R, et al. 2011b. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci 108: 1046-1051.
18. Chambers HF. 2001a. Antimicrobial agents: Protein synthesis inhibitors and miscellaneous antibacterial agents. McGraw-Hill, New York.
19. Chambers HF. 2001b. Antimicrobial agents: The aminoglycosides. McGraw-Hill, New York.
20. Chen J, Zheng XF, Brown EJ, Schreiber SL. 1995. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci 92: 4947-4951.
21. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. 2011a. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117: 156-164.
22. Chen T, Ozel D, Qiao Y, Harbinski F, Chen L, Denoyelle S, He X, Zvereva N, Supko JG, Chorev M, et al. 2011b. Chemical genetics identify eIF2a kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol 7: 610-616.
23. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. 2008. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci 105: 17414-17419.
24. Cruz-Migoni A, Hautbergue GM, Artymiuk PJ, Baker PJ, Bokori-Brown M, Chang CT, Dickman MJ, Essex-Lopresti A, Harding SV, Mahadi NM, et al. 2011. A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science 334: 821-824.
25. Darzynkiewicz E, Antosiewicz J, Ekiel I, Morgan MA, Tahara SM, Shatkin AJ. 1981. Methyl esterification of m7G50p reversibly blocks its activity as an analog of eukaryotic mRNA 50-caps. J Mol Biol 153: 451-458.
26. Darzynkiewicz E, Ekiel I, Lassota P, Tahara SM. 1987. Inhibition of eukaryotic translation by analogues of messenger RNA 5′-cap: Chemical and biological consequences of 50-phosphate modifications of 7-methylguanosine 50- monophosphate. Biochemistry 26: 4372-4380.
27. Darzynkiewicz E, Stepinski J, Ekiel I, Goyer C, Sonenberg N, Temeriusz A, Jin Y, Sijuwade T, Haber D, Tahara SM. 1989. Inhibition of eukaryotic translation by nucleoside 50-monophosphate analogues of mRNA 50-cap: Changes in N7 substituent affect analogue activity. Biochemistry 28: 4771-4778.
28. De Benedetti A, Joshi-Barve S, Rinker-Schaeffer C, Rhoads RE. 1991. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. Mol Cell Biol 11: 5435-5445.
29. DeFatta RJ, Nathan CA, De Benedetti A. 2000. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 110: 928-933.
30. Dobson C, Christodoulou J, Cabrita L. 2012. Cold Spring Harb Persepct Biol doi: 10.1101/cshperspect.a012260.
31. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. 2006. S6K1- and bTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314: 467-471.
32. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, et al. 2010. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328: 1172-1176.
33. Dumez H, Gallardo E, Culine S, Galceran JC, Schoffski P, Droz JP, Extremera S, Szyldergemajn S, Flechon A. 2009. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Mar Drugs 7: 451-463.
34. Duncan R, Milburn SC, Hershey JW. 1987. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem 262: 380-388.
35. El Sous M, Khoo ML, Holloway G, Owen D, Scammells PJ, Rizzacasa MA. 2007. Total synthesis of (2)-episilvestrol and (2)-silvestrol. Angew Chem Int Ed Engl 46: 7835-7838.
36. Fan S, Li Y, Yue P, Khuri FR, Sun SY. 2010. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia 12: 346-356.
37. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. 2009. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.
38. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, et al. 2010. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci 107: 14134-14139.
39. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, Alessi DR. 2009. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421: 29-42.
40. Gerard B, Cencic R, Pelletier J, Porco JA Jr. 2007. Enantioselective synthesis of the complex rocaglate (2)-silvestrol. Angew Chem Int Ed Engl 46: 7831-7834.
41. Ghosh B, Benyumov AO, Ghosh P, Jia Y, Avdulov S, Dahlberg PS, Peterson M, Smith K, Polunovsky VA, Bitterman PB, et al. 2009. Nontoxic chemical interdiction of the epithelial- to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol 4: 367-377.
42. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. 1999a. Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev 13: 1422-1437.
43. Gingras AC, Raught B, Sonenberg N. 1999b. eIF4 initiation factors: Effectors ofmRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963.
44. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. 2001. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15: 2852-2864.
45. Gonzalez N, Barral MA, Rodriguez J, Jimenez C. 2001. New cytotoxic steroids from the gorgonian Isis hippuris. Structure-activity studies. Tetrahedron 57: 3487-3497.
46. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, et al. 2007. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117: 2638-2648.
47. Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. 2007a. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 13: 1745-1755.
48. Grudzien-Nogalska E, Stepinski J, Jemielity J, Zuberek J, Stolarski R, Rhoads RE, Darzynkiewicz E. 2007b. Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability. Methods Enzymol 431: 203-227.
49. Gurel G, Blaha G, Moore PB, Steitz TA. 2009. U2504 determines the species specificity of the A-site cleft antibiotics: The structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 389: 146-156.
50. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
51. Harrington LS, Findlay GM, Lamb RF. 2005. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30: 35-42.
52. Herbert TP, Fahraeus R, Prescott A, Lane DP, Proud CG. 2000. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 10: 793-796.
53. Hickey ED, Weber LA, Baglioni C, Kim CH, Sarma RH. 1977. A relation between inhibition of protein synthesis and conformation of 5′-phosphorylated 7-methylguanosine derivatives. J Mol Biol 109: 173-183.
54. Hidalgo M, Rowinsky EK. 2000. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686.
55. Higa T, Tanaka J, Yasumasa T, Hiroyuki K. 1981. Hippuristanols, cytotoxic polyoxygenated steroids from the gorgonian Isis hippuris. Chem Lett 11: 1647-1650.
56. Holz MK, Ballif BA, Gygi SP, Blenis J. 2005. mTORand S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123: 569-580.
57. Hood KA, West LM, Northcote PT, Berridge MV, Miller JH. 2001. Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine. Apoptosis 6: 207-219.
58. Hwang BY, Su BN, Chai H, Mi Q, Kardono LB, Afriastini JJ, Riswan S, Santarsiero BD, Mesecar AD, Wild R, et al. 2004. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem 69: 3350-3358.
59. Ilic N, Utermark T, Widlund HR, Roberts TM. 2011. PI3Ktargeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci 108: E699-E708.
60. Ingolia NT, Lareau LF, Weissman JS. 2011. Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell 147: 789-802.
61. Jemielity J, Kowalska J, Rydzik AM, Darzynkiewicz E. 2010. Synthetic mRNA cap analogs with a modified triphosphate bridge-Synthesis, applications and prospects. New J Chem 34: 829-844.
62. Jones RM, Branda J, Johnston KA, Polymenis M, Gadd M, Rustgi A, Callanan L, Schmidt EV. 1996. An essential E box in the promoter of the gene encoding themRNAcapbinding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 16: 4754-4764.
63. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. 2001. Homoharringtonine: History, current research, and future direction. Cancer 92: 1591-1605.
64. Kapp LD, Lorsch JR. 2004. The molecular mechanics of eukaryotic translation. Annu Rev Biochem 73: 657-704.
65. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
66. Kim S, Yang JY, Xu J, Jang IC, Prigge MJ, Chua NH. 2008. Two cap-binding proteins CBP20 and CBP80 are involved in processing primary MicroRNAs. Plant Cell Physiol 49: 1634-1644.
67. Kim TD, Frick M, le Coutre P. 2011. Omacetaxine mepesuccinate for the treatment of leukemia. Expert Opin Pharmacother 12: 2381-2392.
68. Ko SY, Guo H, Barengo N, Naora H. 2009. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 15: 4336-4347.
69. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen P, Parsons SH, Ellis KE, et al. 2011. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 71: 1849-1857.
70. Korneeva NL, Lamphear BJ, Hennigan FL, Rhoads RE. 2000. Mutually cooperative binding of eukaryotic translation initiation factor (eIF) 3 and eIF4A to human eIF4G-1. J Biol Chem 275: 41369-41376.
71. Kowalska J, Lewdorowicz M, Zuberek J, Grudzien-Nogalska E, Bojarska E, Stepinski J, Rhoads RE, Darzynkiewicz E, Davis RE, Jemielity J. 2008. Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS. RNA 14: 1119- 1131.
72. Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. 1993. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73: 585-596.
73. Kuznetsov G, Xu Q, Rudolph-Owen L, Tendyke K, Liu J, Towle M, Zhao N, Marsh J, Agoulnik S, Twine N, et al. 2009. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol Cancer Ther 8: 1250-1260.
74. Lawson TG, Ray BK, Dodds JT, Grifo JA, Abramson RD, Merrick WC, Betsch DF, Weith HL, Thach RE. 1986. Influence of 50 proximal secondary structure on the translational efficiency of eukaryotic mRNAs and on their interaction with initiation factors. J Biol Chem 261: 13979-13989.
75. Lawson TG, Cladaras MH, Ray BK, Lee KA, Abramson RD, Merrick WC, Thach RE. 1988. Discriminatory interaction of purified eukaryotic initiation factors 4F plus 4A with the 50 ends of reovirus messenger RNAs. J Biol Chem 263: 7266-7276.
76. Lazaris-Karatzas A, Montine KS, Sonenberg N. 1990. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 50 cap. Nature 345: 544-547.
77. Li W, Dang Y, Liu JO, Yu B. 2009. Expeditious synthesis of hippuristanol and congeners with potent antiproliferative activities. Chemistry 15: 10356-10359.
78. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. 2008. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 68: 5326-5334.
79. Lindqvist L, Oberer M, Reibarkh M, Cencic R, Bordeleau ME, Vogt E, Marintchev A, Tanaka J, Fagotto F, Altmann M, et al. 2008. Selective pharmacological targeting of a DEAD box RNA helicase. PLoS ONE 3: e1583.
80. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, et al. 2011. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 17: 1116-1120.
81. Lorsch J, Dever T, Hinnebusch A, Green R. 2012. Cold Spring Harb Persepct Biol doi: 10.1101/cshperspect.a011544.
82. Low WK, Dang Y, Schneider-Poetsch T, Shi Z, Choi NS, Merrick WC, Romo D, Liu JO. 2005. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell 20: 709-722.
83. Low WK, Dang Y, Bhat S, Romo D, Liu JO. 2007. Substratedependent targeting of eukaryotic translation initiation factor 4A by Pateamine A: Negation of domain-linker regulation of activity. Chem Biol 14: 715-727.
84. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, et al. 2009. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 113: 4656-4666.
85. Maquat LE, Hwang J, Sato H, Tang Y. 2010. CBP80-promoted mRNP rearrangements during the pioneer round of translation, nonsense-mediated mRNA decay, and thereafter. Cold Spring Harb Symp Quant Biol 75: 127-134.
86. Marchetti A, Buttitta F, Miyazaki S, Gallahan D, Smith GH, Callahan R. 1995. Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. J Virol 69: 1932-1938.
87. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. 1997. Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89: 951-961.
88. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, et al. 2008. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci 105: 10853-10858.
89. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, et al. 2007. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128: 257-267.
90. Mothe-Satney I, Yang D, Fadden P, Haystead TA, Lawrence JC Jr. 2000. Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol Cell Biol 20: 3558-3567.
91. Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, Craig-Mueller N, Colinge J, Duernberger G, Nijman SM. 2011. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol 7: 787-793.
92. Niedzwiecka A, Marcotrigiano J, Stepinski J, Jankowska-Anyszka M, Wyslouch-Cieszynska A, Dadlez M, Gingras AC, Mak P, Darzynkiewicz E, Sonenberg N, et al. 2002. Biophysical studies of eIF4E cap-binding protein: Recognition of mRNA 50 cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J Mol Biol 319: 615-635.
93. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F. 2004. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10: 1013-1023.
94. Novac O, Guenier AS, Pelletier J. 2004. Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res 32: 902-915.
95. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
96. Pelletier J, Peltz SW. 2007. Therapeutic opportunities in translation. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
97. Pelletier J, Sonenberg N. 1985a. Insertion mutagenesis to increase secondary structure within the 50 noncoding region of a eukaryoticmRNA reduces translational efficiency. Cell 40: 515-526.
98. Pelletier J, Sonenberg N. 1985b. Photochemical cross-linking of cap binding proteins to eucaryotic mRNAs: Effect of mRNA 50 secondary structure. Mol Cell Biol 5: 3222-3230.
99. Pestka S. 1977. Inhibitors of protein synthesis. Academic Press, New York.
100. Pruvot B, Jacquel A, Droin N, Auberger P, Bouscary D, Tamburini J, Muller M, Fontenay M, Chluba J, Solary E. 2011. Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. Haematologica 96: 612-616.
101. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. 1999. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 18: 270-279.
102. Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL, Polakiewicz RD, Sonenberg N, Hershey JW. 2004. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 23: 1761-1769.
103. Ravindar K, Reddy MS, Lindqvist L, Pelletier J, Deslongchamps P. 2010. Efficient synthetic approach to potent antiproliferative agent hippuristanol via Hg(II)-catalyzed spiroketalization. Org Lett 12: 4420-4423.
104. Ravindar K, Reddy MS, Lindqvist L, Pelletier J, Deslongchamps P. 2011. Synthesis of the antiproliferative agent hippuristanol and its analogues via Suarez cyclizations and Hg(II)-catalyzed spiroketalizations. J Org Chem 76: 1269-1284.
105. Rinker-Schaeffer CW, Graff JR, De Benedetti A, Zimmer SG, Rhoads RE. 1993. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer 55: 841-847.
106. Robert F, Kapp LD, Khan SN, Acker MG, Kolitz S, Kazemi S, Kaufman RJ, Merrick WC, Koromilas AE, Lorsch JR, et al. 2006. Initiation of protein synthesis by hepatitis C virus is refractory to reduced eIF2.GTP.Met-tRNAiMet ternary complex availability. Mol Biol Cell 17: 4632-4644.
107. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. 2009. Altering chemosensitivity by modulating translation elongation. PLoS ONE 4: e5428.
108. Roche SP, Cencic R, Pelletier J, Porco JA Jr. 2010. Biomimetic photocycloaddition of 3-hydroxyflavones: Synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation. Angew Chem Int Ed Engl 49: 6533-6538.
109. Rogers GW Jr, Komar AA, Merrick WC. 2002. eIF4A: The godfather of the DEAD box helicases. Prog Nucleic Acid Res Mol Biol 72: 307-331.
110. Rosenwald IB. 1996. Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF- 2a in transformed cells. Cancer Lett 102: 113-123.
111. Rosenwald IB, Wang S, Savas L, Woda B, Pullman J. 2003. Expression of translation initiation factor eIF-2a is increased in benign and malignant melanocytic and colonic epithelial neoplasms. Cancer 98: 1080-1088.
112. Rosenwald IB, Koifman L, Savas L, Chen JJ, Woda BA, Kadin ME. 2008. Expression of the translation initiation factors eIF-4E and eIF-2α is frequently increased in neoplastic cells of Hodgkin lymphoma. Hum Pathol 39: 910-916.
113. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon- Cardo C, Pandolfi PP. 2004. The translation factor eIF-4E promotes tumor formation and cooperateswith c-Myc in lymphomagenesis. Nat Med 10: 484-486.
114. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. 1994. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78: 35-43.
115. Saradhi UV, Gupta SV, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, et al. 2011. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J 13: 347-356.
116. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin- insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
117. Satheesha S, Cookson VJ, Coleman LJ, Ingram N, Madhok B, Hanby AM, Suleman CA, Sabine VS, Macaskill EJ, Bartlett JM, et al. 2011. Response to mTOR inhibition: Activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol Cancer 10: 19.
118. Schatz JH, Oricchio E, Wolfe AL, Jiang M, Linkov I, Maragulia J, Shi W, Zhang Z, Rajasekhar VK, Pagano NC, et al. 2011. Targeting cap-dependent translation blocks converging survival signals by AKTand PIM kinases in lymphoma. J Exp Med 208: 1799-1807.
119. Schwartz DC, Parker R. 2000. mRNA decapping in yeast requires dissociation of the cap binding protein, eukaryotic translation initiation factor 4E. Mol Cell Biol 20: 7933-7942.
120. Sengupta S, Peterson TR, Sabatini DM. 2010. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40: 310-322.
121. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N. 2006. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25: 2781-2791.
122. Shatkin AJ, Darzynkiewicz E, Furuichi Y, Kroath H, Morgan MA, Tahara SM, Yamakawa M. 1982. 50-Terminal caps, cap-binding proteins and eukaryotic mRNA function. Biochem Soc Symp 47: 129-143.
123. Silvera D, Formenti SC, Schneider RJ. 2010. Translational control in cancer. Nat Rev Cancer 10: 254-266.
124. Solimini NL, Luo J, Elledge SJ. 2007. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130: 986-988.
125. Su W, Slepenkov S, Grudzien-Nogalska E, Kowalska J, Kulis M, Zuberek J, Lukaszewicz M, Darzynkiewicz E, Jemielity J, Rhoads RE. 2011. Translation, stability, and resistance to decapping of mRNAs containing caps substituted in the triphosphate chain with BH3, Se, and NH. RNA 17: 978-988.
126. Takacs JE, Neary TB, Ingolia NT, Saini AK, Martin-Marcos P, Pelletier J, Hinnebusch AG, Lorsch JR. 2011. Identification of compounds that decrease the fidelity of start codon recognition by the eukaryotic translational machinery. RNA 17: 439-452.
127. Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z, Legrand O, Marie JP. 2006. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia- 1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 5: 723-731.
128. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. 2009. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032.
129. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, Oyarzabal J, Pastor J, Bischoff JR, Fernandez-Capetillo O. 2011. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 18: 721-727.
130. Topisirovic I, Ruiz-Gutierrez M, Borden KL. 2004. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation andmRNAtransport activities. Cancer Res 64: 8639-8642.
131. Tsumuraya T, Ishikawa C, Machijima Y, Nakachi S, Senba M, Tanaka J, Mori N. 2011. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol 81: 713-722.
132. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. 2004. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24: 6539-6549.
133. Vazquez D. 1979. Inhibitors of protein biosynthesis. Mol Biol Biochem Biophys 30: 1-312.
134. Wagner CR, Iyer VV, McIntee EJ. 2000. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev 20: 417-451.
135. Wander SA, Hennessy BT, Slingerland JM. 2011. Next-generationmTORinhibitors in clinical oncology:How pathway complexity informs therapeutic strategy. J Clin Invest 121: 1231-1241.
136. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
137. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon- Cardo C, Pelletier J, Lowe SW. 2006. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 66: 7639-7646.
138. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, et al. 2007. Dissecting eIF4E action in tumorigenesis. Genes Dev 21: 3232-3237.
139. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, et al. 2010. Beyond rapalog therapy: Preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 70: 621-631.
140. Yuan TL, Cantley LC. 2008. PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27: 5497-5510.
141. Zhang L, Pan X, Hershey JW. 2007. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem 282: 5790-5800.
142. Zhang L, Smit-McBride Z, Pan X, Rheinhardt J, Hershey JW. 2008. An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3. J Biol Chem 283: 24047-24060.